SynthesisJournal of hematology & oncology2018
Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review.
Synthesis in Journal of hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 77 citations in OpenAlex.
- Real-World Outcomes of Frontline Multimodal Treatment Strategies for Localized Extranodal NK/T-Cell Lymphoma, Nasal Type: A Single-Center Vietnamese Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
- Nasal type of extranodal NK/T-cell lymphoma presenting as an atypical skin defect: A case report.Medicine · 2026Article
- Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.Blood advances · 2026Article
- Clinicopathologic implications of sphingosine-1-phosphate pathway in extranodal NK/T-cell lymphoma according to immune subtype.Scientific reports · 2026Article
- The prognostic predictive SER model for NK/T-cell lymphoma in the era of modern immunotherapy.Cancer cell international · 2026Article
- The impact of chemotherapy relative dose intensity on survival in elderly patients with extranodal NK/T-cell lymphoma: A retrospective cohort study.Therapeutic advances in hematology · 2026Article
- Peripheral blood immune profiling reveals key signatures in newly diagnosed NK/T cell lymphoma patients.Theranostics · 2026Article
- Characterizing tumor microenvironment heterogeneity in EBVFrontiers in immunology · 2026Article
- GNAQ inhibits tumorigenesis via the ARHGEF25-mediated RHOA pathway in NK/T-cell lymphoma.Cancer biology & therapy · 2025Article
- Mature NK-cell lymphoma presenting with chylothorax and delirium: a rare emergency case.International journal of emergency medicine · 2025Article
- Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States.JMIR formative research · 2025Article
- Development of a Radiomic-clinical Nomogram for Prediction of Survival in Patients with Nasal Extranodal Natural Killer/T-cell LymphomaCurrent medical imaging · 2025Article
- Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?Advances in radiation oncology · 2024Article
- Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma.Chinese medical journal · 2024Review
- Wait and see: a case of EBV + cutaneous extranodal NK/T-type lymphoma with indolent behaviour.Virchows Archiv : an international journal of pathology · 2024Article
- Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging.Cell reports. Medicine · 2024Article
- Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center.Frontiers in oncology · 2024Article
- A Nomogram Model Based on the Inflammation-Immunity-Nutrition Score (IINS) and Classic Clinical Indicators for Predicting Prognosis in Extranodal Natural Killer/T-Cell Lymphoma.Journal of inflammation research · 2024Article
- Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.Cancer reports (Hoboken, N.J.) · 2023Article
- A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK.Cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non-anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.